News from Portfolio Companies

New Ventures News and Publications

  • Ulo Palm on P-Values: What They Are and Why They’re Past Their Prime
    Episode Summary This week Harry quizzes Ulo Palm, the senior vice president of digital sciences at Allergan, about the long and problematic reign of the p-value in statistical analysis, and why it may be time for the biopharma industry to look to more nuanced measures of whether a drug trial succeeded. Episode Notes Though the p-value “determines everything we do ...
  • Enterin to Conduct a Randomized Phase 1/2a Study in Hospitalized Patients With COVID-19
    PHILADELPHIA, April 17, 2020 /PRNewswire/ — Enterin, Inc., a clinical-stage company focused on neurodegenerative diseases, announced today that it has received feedback from the FDA laying out the path for a Phase 1/2a study in hospitalized patients with COVID-19 infection. The study will involve 10 U.S. sites and will enroll 80 hospitalized patients. Patients will have been diagnosed with SARS-CoV-2, have an SpO2 ...
  • How Data Is Critical to Engineering Antibodies to Block COVID-19
    Episode Summary Distributed Bio aims to use its computational antibody engineering platform to identify antibodies that protect against SARS and optimize them to block the SARS-CoV2 coronavirus. This week Harry gets an progress update from three key Distributed Bio scientists. Episode Notes Building on his March 2020 interview with Jake Glanville, the founding partner and CEO of South San Francisco-based ...
  • Jacob Glanville Confronts Coronavirus Through Immuno-engineering
    Episode Summary Harry’s guest for this unusually frank and urgent episode is Jacob Glanville, the founding partner, CEO, and president of Distributed Bio. The company is using its skills in computational antibody analysis and optimization to help the drug industry develop new vaccines and antibody-based treatments for a range of diseases, potentially including the coronavirus that causes COVID-19. Episode Notes ...
  • Ramy Farid on the Power of Computation in Drug Discovery
    Episode Summary Harry interviews Ramy Farid, president and CEO of Schrödinger Pharmaceuticals, about the company’s success using chemical simulation software to help drug makers zero in on promising drug candidates—and about its recent IPO, which brought in more than twice as much cash as the company expected. Episode Notes Schrödinger makes software that models the physics of atomic-scale interactions to ...
  • Illumina’s Phil Febbo on Sequencing, Coronavirus and Viral Outbreaks
    Episode Summary As the Wuhan coronavirus outbreak spreads in Asia, Harry speaks with Phil Febbo, the chief medical officer of Illumina, one of the world’s largest makers of equipment for high-throughput DNA sequencing. Febbo highlights sequencing’s emerging contribution to the understanding and treatment of infectious disease. Episode Notes Rapid sequencing of viral genomes is giving physicians and epidemiologists new ways ...
  • Daniella Gilboa on How Deep Learning Can Revolutionize IVF
    Episode Summary: Daniella Gilboa is an embryologist in Israel working to bring the power of AI and machine learning to the embryo selection phase of IVF treatment. She explains how her new startup aims to automate this error-ridden process, raising efficiency and lowering the overall cost of IVF. Episode Notes: Doctors helping couples conceive through in-vitro fertilization typically must screen ...
  • Drug developers take fresh aim at ‘guided-missile’ cancer drugs
    John Miller Ludwig Burger Published: Jan 06 at 11:08 a.m. By Ludwig Burger and John Miller FRANKFURT/ZURICH (Reuters) – Dozens of drugmakers are conducting human trials for a record 89 therapies that pair antibodies with toxic agents to fight cancer, evidence of renewed confidence in an approach that has long fallen short of its promise, an analysis compiled for Reuters shows. ...
  • Tom Davenport on the Analytics Gap in Healthcare
    Episode Summary Harry’s guest this week is Tom Davenport, who argues that the healthcare industry is way behind in its use of big-data analytics software to make smarter decisions about business and patient care. “This is a period of lots of opportunity to use new technologies to change healthcare, and God knows we need it, from a value-for-expense standpoint,” Davenport ...
  • Milind Kamkolkar on Seeing the Forest and the Trees at Cellarity
    Episode Summary: Harry welcomes Milind Kamkolkar back to the program. The former Sanofi exec is now the chief data and digital officer at Cellarity, a Flagship Pioneering-backed therapeutics startup working to model cell behavior computationally in order to identify new drug targets and therapies. Episode Notes: Milind Kamkolkar joined Cellarity in January 2019 to help the company to prove that ...